NVCT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NV

Mkt Cap

$607.5M

Volume

128.67K

Next Earnings

November 3rd

Loading chart

NV

NVCTNuvectis Pharma, Inc. Common Stock

NVCT

Pay with—

Available Balance0.00

NV

Mkt Cap

$618.0M

Volume

128.67K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common StockNuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 5 million shares at $20.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to advance development of its pipeline candidates NXP100, NXP200, and NXP900, hire personnel, and cover operational expenses. The offering is expected to close on July 1, 2026.GlobeNewswire Inc. · Jun 30, 2026

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingNuvectis Pharma announced three poster presentations for its clinical-stage drug NXP900, a first-in-class YES1/SRC inhibitor, at the 2026 AACR Meeting in San Diego (April 17-22). The presentations will showcase NXP900's synergy with KRAS inhibitors in NSCLC models, strategies to overcome drug resistance in cholangiocarcinoma, and its potential to restore antitumor immunity by targeting myeloid-derived suppressor cells.GlobeNewswire Inc. · Mar 31, 2026

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common StockNuvectis Pharma, a clinical-stage biopharmaceutical company, announced the pricing of its $13.5 million public offering of 2.7 million shares of common stock at $5 per share. The company plans to use the proceeds to advance the development of its drug candidates NXP800 and NXP900.GlobeNewswire Inc. · Feb 5, 2025

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business HighlightsNuvectis Pharma, Inc. reported its Q3 2024 financial results and provided updates on the development of its drug candidates NXP800 and NXP900. The company expects a clinical data update for NXP800 this month and has progressed the NXP900 Phase 1a study with no dose-limiting toxicities.GlobeNewswire Inc. · Nov 5, 2024

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal CancersNuvectis Pharma announced that the FDA granted Orphan Drug Designation for its drug candidate NXP800 to treat a subset of ovarian cancer with ARID1a deficiency. This designation provides financial incentives and potential marketing exclusivity if the drug is approved.GlobeNewswire Inc. · Aug 29, 2024

Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.Zacks Investment Research · May 24, 2024

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceFort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.GlobeNewswire Inc. · May 16, 2024

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business HighlightsFORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2024 and provided an update on recent business progress.GlobeNewswire Inc. · May 7, 2024

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesGlobeNewswire Inc. · Apr 8, 2024

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research MeetingFort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2024 American Association for Cancer Research Meeting (2024 AACR), taking place from April 5th to April 10th in San Diego, California. Presentation details are below:GlobeNewswire Inc. · Mar 19, 2024

to start trading

NV

NVCTNuvectis Pharma, Inc. Common Stock

NVCT

Pay with—

Available Balance0.00

Your PositionYou don't own any NVCT yet.

Related Tickers

Earnings